|
Federal Register
Notices > Importers 2008 >
Sigma Aldrich Manufacturing LLC
FR Doc E8-3182 [Federal Register: February 21, 2008 (Volume 73, Number 35)]
[Notices] [Page 9589-9590] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr21fe08-88]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a
registration under this section to a bulk manufacturer of a controlled substance
in schedule I or II, and prior to issuing a registration under 21
U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers
holding registrations for the bulk manufacture of the substance an opportunity
for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations (CFR),
1301.34(a), this is notice that on January 10, 2008, Sigma Aldrich Manufacturing
LLC., 3500 Dekalb Street, St. Louis, Missiouri 63118, made application to the
Drug Enforcement Administration (DEA) to be registered as an importer of the
basic classes of controlled substances listed in schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
Aminorex (1585)
|
I
|
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
|
Methaqualone (2565)
|
I
|
|
Ibogaine (7260)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
Marihuana (7360)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (MDMA) (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Bufotenine (7433)
|
I
|
|
Diethyltryptamine (7434)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
N-Ethyl-1-phenylcyclohexylamine (7455)
|
I
|
|
N-Benzylpiperazine (BZP) (7493)
|
I
|
|
Trifluoromethylphenyl Piperazine (7494)
|
I
|
|
Heroin (9200)
|
I
|
|
Normorphine (9313)
|
I
|
|
Etonitazene (9624)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Glutethimide (2550)
|
II
|
|
Nabilone (7379)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Diprenorphine (9058)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Diphenoxylate (9170)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Opium powdered (9639)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to import the listed controlled substances for sale to
research facilities for drug testing and analysis.
Any bulk manufacturer who is presently, or is applying to be, registered with
DEA to manufacture such basic classes of controlled substances may file comments
or objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative/ODL, Washington, DC 20537, or
any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative/ODL,
8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than
March 24, 2008.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a
previous notice published in the Federal Register on September 23, 1975, (40 FR
43745), all applicants for registration to import a basic class of any
controlled substances in schedule I or II are, and will continue to be, required
to demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for such
registration pursuant to 21
U.S.C. 958(a); 21
U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: February 13, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-3182 Filed 2-20-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|